Form 4: Puma Biotechnology Director Executes Stock Transactions

Director Allison Dorval acquired 27,000 restricted stock units and sold 11,610 shares of Puma Biotechnology common stock.

Summary

• Director Allison Dorval acquired 27,000 shares of common stock via restricted stock units on June 11, 2026.
• Director Allison Dorval sold 11,610 shares of common stock on June 12, 2026, at a weighted average price of $7.1989 per share.
• The sale was conducted pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025.
• Following these transactions, the director holds 90,780 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was executed under a pre-existing 10b5-1 plan and represents routine portfolio management by a director.

Positives

• The director maintains a significant equity stake of 90,780 shares in the company.

Negatives

• The director reduced their total beneficial ownership by 11,610 shares through a market sale.

Risks

• Future share price volatility may impact the value of the director's remaining holdings.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or financial performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under pre-arranged 10b5-1 plans, are standard corporate governance practices and generally reflect personal financial planning rather than a change in sentiment regarding the company's strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a standard industry practice for corporate insiders to avoid potential conflicts of interest or allegations of insider trading.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Puma Biotechnology, PBYI, Insider Trading, Form 4, Director Transaction, Equity Compensation